American Society of Hirudotherapy

Symbiont succession during embryonic development of the European medicinal leech, Hirudo verbana

Research article published in Appl Environ Microbiol (2009)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Basic science (non-clinical)Safety & Infection ControlRio RV et al. · Appl Environ Microbiol, 2009

Abstract

The European medicinal leech, Hirudo verbana, harbors simple microbial communities in the digestive tract and bladder. The colonization history, infection frequency, and growth dynamics of symbionts through host embryogenesis are described using diagnostic PCR and quantitative PCR. Symbiont species displayed diversity in temporal establishment and proliferation through leech development.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.S.
Indexed MeSH termsAnimalsBacteriaBiodiversityDNA, BacterialDNA, RibosomalGastrointestinal TractLeechesPolymerase Chain ReactionRNA, Ribosomal, 16S

Summary

In the European medicinal leech Hirudo verbana, whose digestive tract and bladder harbor microbial communities, diagnostic and quantitative PCR tracked symbiont colonization history, infection frequency, and growth dynamics through embryonic development, revealing diversity among species in the timing of establishment and proliferation.

Why This Matters for Hirudotherapy

This study used diagnostic PCR and quantitative PCR to characterize the colonization history, infection frequency, and growth dynamics of symbiotic bacteria in the digestive tract and bladder of the European medicinal leech (Hirudo verbana) throughout host embryonic development. The authors found that different symbiont species displayed diversity in their timing of establishment and proliferation during leech development. Understanding how microbial symbionts colonize medicinal leeches may inform future strategies for managing leech-associated infection risk in hirudotherapy. However, the study is purely descriptive basic biology with no therapeutic, clinical, or infection-control endpoints, and does not address hirudotherapy practice, anticoagulation, or the leech secretome.

Citation

Reference (Vancouver style)

Rio RV, Maltz M, McCormick B, Reiss A, Graf J. Symbiont succession during embryonic development of the European medicinal leech, Hirudo verbana. Appl Environ Microbiol. 2009;75(21):6890-6895. doi:10.1128/AEM.01129-09. PMID: 19648363

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

DOIPubMed

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.